Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ab&B Bio-Tech CO., LTD. JS Class H ( (HK:2627) ) has issued an update.
Ab&B Bio-Tech CO., LTD. JS, a Chinese vaccine developer specializing in premium and innovative vaccines aimed at replacing traditional and imported products in China while expanding globally, is advancing a pipeline that includes a trivalent subunit influenza vaccine and a lyophilized human rabies vaccine candidate among other vaccine projects. The company announced that China’s National Medical Products Administration has approved its new drug application for a trivalent subunit influenza vaccine for all age groups, marking the first and only such vaccine approved in China at full dosage level, which offers enhanced protection, high antigen purity and lower risk of adverse reactions compared with traditional split-virion vaccines; however, the company cautioned that there is no assurance it will successfully develop and commercialize the product for all intended age groups, signaling both a notable regulatory milestone and ongoing development risk for investors and other stakeholders.
The most recent analyst rating on (HK:2627) stock is a Sell with a HK$47.00 price target. To see the full list of analyst forecasts on Ab&B Bio-Tech CO., LTD. JS Class H stock, see the HK:2627 Stock Forecast page.
More about Ab&B Bio-Tech CO., LTD. JS Class H
Ab&B Bio-Tech CO., LTD. JS is a China-based vaccine company focused on the research, development, manufacturing and commercialization of innovative and traditional vaccines using new technical methods. The company targets premium vaccines designed to replace traditional and imported products in the Chinese market while building a presence internationally, with a pipeline that includes a trivalent subunit influenza vaccine and a lyophilized human rabies vaccine candidate, among other vaccine projects.
Average Trading Volume: 211,994
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$20.18B
For an in-depth examination of 2627 stock, go to TipRanks’ Overview page.